Keens T, Hoffman V, Topuria I, Elder K, Cerf S, Mulder K, Roberts J, Lysinger J, Del Carmen Reyes M, Berdella M, Cairns AM, Jain M, Ganapathy V, Lou Y, Morcos B, Wu C, Sass L, VX19-CFD-003 Study Group. Real-world effectiveness of elexacaftor/tezacaftor/ivacaftor on the burden of illness in adolescents and adults with cystic fibrosis. Heliyon. 2024 Mar 26;10(7):e28508. doi: 10.1016/j.heliyon.2024.e28508
McKenna SP, Doward LC. How should we measure quality of life in ankylosing spondylitis? Rheumatol Pract. 2008;6(2):12-4.
Talmud PJ, Hawe E, Miller GJ. Analysis of gene-environment interaction in coronary artery disease: lipoprotein lipase and smoking as examples. J Cardiovasc Med. 2002;3(1):6-9 Revie.